178 related articles for article (PubMed ID: 38553074)
1. Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study).
Hughes SE; McMullan C; Aiyegbusi OL; Shaw K; Kinsella F; Ferguson P; Khatsuria F; Burns D; Pyatt L; Ansell J; Chakera E; Richardson-Abraham J; Denniston AK; Davies EH; Craddock C; Calvert M
BMJ Open; 2024 Mar; 14(3):e085392. PubMed ID: 38553074
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
Chakraborty R; Sidana S; Shah GL; Scordo M; Hamilton BK; Majhail NS
Biol Blood Marrow Transplant; 2019 May; 25(5):e155-e162. PubMed ID: 30500439
[TBL] [Abstract][Full Text] [Related]
3. Development and usability testing of an electronic patient-reported outcome (ePRO) solution for patients with inflammatory diseases in an Advanced Therapy Medicinal Product (ATMP) basket trial.
McMullan C; Retzer A; Hughes SE; Aiyegbusi OL; Bathurst C; Boyd A; Coleman J; Davies EH; Denniston AK; Dunster H; Frost C; Harding R; Hunn A; Kyte D; Malpass R; McNamara G; Mitchell S; Mittal S; Newsome PN; Price G; Rowe A; van Reil W; Walker A; Wilson R; Calvert M
J Patient Rep Outcomes; 2023 Oct; 7(1):98. PubMed ID: 37812323
[TBL] [Abstract][Full Text] [Related]
4. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of a new electronic patient-reported outcome (ePRO) system for an advanced therapy clinical trial in immune-mediated inflammatory disease (PROmics): protocol for a qualitative feasibility study.
Hughes SE; McMullan C; Rowe A; Retzer A; Malpass R; Bathurst C; Davies EH; Frost C; McNamara G; Harding R; Price G; Wilson R; Walker A; Newsome PN; Calvert M
BMJ Open; 2022 Sep; 12(9):e063199. PubMed ID: 36691123
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
7. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
8. Use of an electronic patient-reported outcome measure in the management of patients with advanced chronic kidney disease: the RePROM pilot trial protocol.
Kyte D; Bishop J; Brettell E; Calvert M; Cockwell P; Dutton M; Eddington H; Hadley G; Ives NJ; Jackson LJ; Stringer S; Valente M
BMJ Open; 2018 Oct; 8(10):e026080. PubMed ID: 30373785
[TBL] [Abstract][Full Text] [Related]
9. Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial.
Tran C; Dicker A; Leiby B; Gressen E; Williams N; Jim H
J Med Internet Res; 2020 Mar; 22(3):e12689. PubMed ID: 32209536
[TBL] [Abstract][Full Text] [Related]
10. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
13. Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy.
Wilson M; Thavorn K; Hawrysh T; Graham ID; Atkins H; Kekre N; Coyle D; Lalu MM; Fergusson DA; Chan KK; Ollendorf DA; Presseau J
BMJ Open; 2021 Aug; 11(8):e046707. PubMed ID: 34385243
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Lalu MM; Kekre N; Montroy J; Ghiasi M; Hay K; McComb S; Weeratna R; Atkins H; Hutton B; Yahya A; Masurekar A; Sobh M; Fergusson DA
Syst Rev; 2023 Jan; 12(1):9. PubMed ID: 36653879
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
18. Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design.
Fyfe R; Anstis O; Kapadia K; Jordan M; Sword DO; Weinkove R
BMJ Open; 2024 Jan; 14(1):e071112. PubMed ID: 38262637
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.
Wang XS; Srour SA; Mendoza T; Whisenant M; Subbiah I; Gonzalez E; Kamal M; Shen SE; Cleeland C; Kebriaei P; Rezvani K; Neelapu S; Ahmed S; Shpall E
Br J Haematol; 2023 May; 201(4):738-746. PubMed ID: 36733986
[TBL] [Abstract][Full Text] [Related]
20. Design and evaluation of a digital health intervention with proactive follow-up by nurses to improve healthcare and outcomes for patients with breast cancer in Mexico: protocol for a randomised clinical trial.
Contreras Sánchez SE; Doubova SV; Grajales Álvarez R; Dip Borunda AK; Martínez Pineda WJ; Nuñez Cerrillo JG; Silva Bravo F; Zalapa Velázquez R; Gutiérrez De la Barrera M; Leslie HH
BMJ Open; 2023 Nov; 13(11):e077322. PubMed ID: 37931967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
